FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
Amro M. Abdelrahman(Mayo Clinic in Arizona), Mark J. Truty(Mayo Clinic in Arizona), Roberto Alva‐Ruiz(Mayo Clinic in Arizona), Sean P. Cleary(University Health Network), Wen Wee(Roswell Park Comprehensive Cancer Center), Nguyen H. Tran(The University of Sydney), Travis E. Grotz(Mayo Clinic in Arizona), Jennifer A. Yonkus(Mayo Clinic in Arizona), Rondell P. Graham(Mayo Clinic in Arizona), Cornelius A. Thiels(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), Susanne G. Warner(Pancreas Centre (Canada)), David M. Nagorney(Mayo Clinic in Arizona), Rory L. Smoot(Pancreas Centre (Canada)), Michael G. Haddock(Mayo Clinic in Arizona), Ajit H. Goenka(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Þorvarður R. Hálfdánarson(Mayo Clinic), Robert R. McWilliams(Mayo Clinic in Arizona), Michael L. Kendrick, Jennifer L. Leiting(Mayo Clinic)
Cited by 59
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k